BACKGROUND: Even though patients with prostate cancer commonly respond to endocrine treatment, in most cases the disease progresses to castration resistant prostate cancer (CRPC). Our objective was to generate a novel cell line model representing the endocrine treatment naive prostate cancer for testing treatments that target the androgen receptor (AR) and androgen metabolism. METHODS: After culturing DuCaP cells 20 passages with additional 1 nM R1881, DuCaP-N(aive) cell line was developed and validated for testing endocrine therapy combinations. Cell viability, apoptosis and cell cycle distribution were assessed in DuCaP and DuCaP-N when interfering with the hormonal content. RESULTS: Addition of 1 nM R1881 to DuCaP reduces cell viability and induces cell cycle inhibition and apoptosis. Eventually, an androgen accustomed DuCaP-N cell line developed. An antiandrogen (bicalutamide), a histone deacetylase (HDAC) inhibitor (trichostatin A) and a 5alpha-reductase (SRD5A) inhibitor (finasteride) reduce cell viability, and their combinations give a synergistic response in inducing apoptosis. CONCLUSIONS: The TMPRSS2-ERG expressing DuCaP-N cell line represents human prostate cancer prior to endocrine treatment, and its parental DuCaP cell line is a model for CRPC. These cell lines can be used for preclinical evaluation of compounds that target the androgenic pathway. (c) 2010 Wiley-Liss, Inc
BACKGROUND: Even though patients with prostate cancer commonly respond to endocrine treatment, in most cases the disease progresses to castration resistant prostate cancer (CRPC). Our objective was to generate a novel cell line model representing the endocrine treatment naive prostate cancer for testing treatments that target the androgen receptor (AR) and androgen metabolism. METHODS: After culturing DuCaP cells 20 passages with additional 1 nM R1881, DuCaP-N(aive) cell line was developed and validated for testing endocrine therapy combinations. Cell viability, apoptosis and cell cycle distribution were assessed in DuCaP and DuCaP-N when interfering with the hormonal content. RESULTS: Addition of 1 nM R1881 to DuCaP reduces cell viability and induces cell cycle inhibition and apoptosis. Eventually, an androgen accustomed DuCaP-N cell line developed. An antiandrogen (bicalutamide), a histone deacetylase (HDAC) inhibitor (trichostatin A) and a 5alpha-reductase (SRD5A) inhibitor (finasteride) reduce cell viability, and their combinations give a synergistic response in inducing apoptosis. CONCLUSIONS: The TMPRSS2-ERG expressing DuCaP-N cell line represents humanprostate cancer prior to endocrine treatment, and its parental DuCaP cell line is a model for CRPC. These cell lines can be used for preclinical evaluation of compounds that target the androgenic pathway. (c) 2010 Wiley-Liss, Inc
Authors: Agus Rizal A H Hamid; Minja J Pfeiffer; Gerald W Verhaegh; Ewout Schaafsma; Andre Brandt; Fred C G J Sweep; John P M Sedelaar; Jack A Schalken Journal: Mol Med Date: 2013-01-22 Impact factor: 6.354
Authors: Julia Hoefer; Johann Kern; Philipp Ofer; Iris E Eder; Georg Schäfer; Dimo Dietrich; Glen Kristiansen; Stephan Geley; Johannes Rainer; Eberhard Gunsilius; Helmut Klocker; Zoran Culig; Martin Puhr Journal: Endocr Relat Cancer Date: 2014-01-30 Impact factor: 5.678
Authors: Andrea Köhler; Ummühan Demir; Eva Kickstein; Sybille Krauss; Johanna Aigner; Beatriz Aranda-Orgillés; Antonios I Karagiannidis; Clemens Achmüller; Huajie Bu; Andrea Wunderlich; Michal-Ruth Schweiger; Georg Schaefer; Susann Schweiger; Helmut Klocker; Rainer Schneider Journal: Mol Cancer Date: 2014-06-09 Impact factor: 27.401